492 related articles for article (PubMed ID: 32203305)
21. The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
Rodrigues DN; Boysen G; Sumanasuriya S; Seed G; Marzo AM; de Bono J
J Pathol; 2017 Jan; 241(2):173-182. PubMed ID: 27753448
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
Sheehan B; Guo C; Neeb A; Paschalis A; Sandhu S; de Bono JS
Eur Urol Focus; 2022 Sep; 8(5):1157-1168. PubMed ID: 34167925
[TBL] [Abstract][Full Text] [Related]
23. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
24. Targeted nanomedicine modalities for prostate cancer treatment.
Cohen L; Livney YD; Assaraf YG
Drug Resist Updat; 2021 May; 56():100762. PubMed ID: 33857756
[TBL] [Abstract][Full Text] [Related]
25. Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance.
Höti N; Shah P; Hu Y; Yang S; Zhang H
Proteomics; 2017 Mar; 17(6):. PubMed ID: 28116790
[TBL] [Abstract][Full Text] [Related]
26. [Prostate cancer and apoptosis].
Mayora A; Arvelo F
Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
[TBL] [Abstract][Full Text] [Related]
27. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
28. Advances in prostate cancer chemotherapy: a new era begins.
Pienta KJ; Smith DC
CA Cancer J Clin; 2005; 55(5):300-18; quiz 323-5. PubMed ID: 16166075
[TBL] [Abstract][Full Text] [Related]
29. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling.
Mousses S; Wagner U; Chen Y; Kim JW; Bubendorf L; Bittner M; Pretlow T; Elkahloun AG; Trepel JB; Kallioniemi OP
Oncogene; 2001 Oct; 20(46):6718-23. PubMed ID: 11709706
[TBL] [Abstract][Full Text] [Related]
30. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
31. A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery.
Tian JY; Chi CL; Bian G; Guo FJ; Wang XQ; Yu B
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):195-203. PubMed ID: 32991779
[TBL] [Abstract][Full Text] [Related]
32. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
33. Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.
Awad D; Pulliam TL; Lin C; Wilkenfeld SR; Frigo DE
Curr Opin Pharmacol; 2018 Aug; 41():1-11. PubMed ID: 29609138
[TBL] [Abstract][Full Text] [Related]
34. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Nouri M; Caradec J; Lubik AA; Li N; Hollier BG; Takhar M; Altimirano-Dimas M; Chen M; Roshan-Moniri M; Butler M; Lehman M; Bishop J; Truong S; Huang SC; Cochrane D; Cox M; Collins C; Gleave M; Erho N; Alshalafa M; Davicioni E; Nelson C; Gregory-Evans S; Karnes RJ; Jenkins RB; Klein EA; Buttyan R
Oncotarget; 2017 Mar; 8(12):18949-18967. PubMed ID: 28145883
[TBL] [Abstract][Full Text] [Related]
35. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
36. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of prostate cancer progression to androgen independence.
McPhaul MJ
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms leading to the development of hormone-resistant prostate cancer.
Kasper S; Cookson MS
Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
[TBL] [Abstract][Full Text] [Related]
39. The hurdle of antiandrogen drug resistance: drug design strategies.
Trendel JA
Expert Opin Drug Discov; 2013 Dec; 8(12):1491-501. PubMed ID: 24206221
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer: a dynamic illness with shifting targets.
Shaffer DR; Scher HI
Lancet Oncol; 2003 Jul; 4(7):407-14. PubMed ID: 12850191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
